This is the talk page for discussing improvements to the Lung cancer article. This is not a forum for general discussion of the article's subject. |
Article policies |
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives: 1, 2, 3, 4Auto-archiving period: 6 months |
Lung cancer is a featured article; it (or a previous version of it) has been identified as one of the best articles produced by the Wikipedia community. Even so, if you can update or improve it, please do so. | ||||||||||||||||||||||
This article appeared on Wikipedia's Main Page as Today's featured article on November 18, 2007, and on July 5, 2023. | ||||||||||||||||||||||
|
This level-4 vital article is rated FA-class on Wikipedia's content assessment scale. It is of interest to multiple WikiProjects. | ||||||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Lung cancer.
|
There is a request, submitted by Catfurball, for an audio version of this article to be created. For further information, see WikiProject Spoken Wikipedia. The rationale behind the request is: "Important". |
Hi, I reverted the following edit so that we can work together to ensure the source and material meets Wikipedia:Identifying reliable sources (medicine). Here is the edit: "According to a study for which results were presented at American Society of Clinical Ontology (ASCO), the patients who underwent removal of their tumors and subsequently took a specific drug on daily basis experienced a remarkable reduction in almost 51 percent of death risks.<ref>{{Cite web |title=Lung Cancer Pill Reduces the Death Risk to Half: Clinical Trial Shows |url=https://www.gcatglance.com/2023/06/lung-cancer-pill-reduces-death-risk-to-half.html |access-date=2023-06-05}}</ref>" JenOttawa (talk) 13:19, 5 June 2023 (UTC)
advanced non–small-cell lung cancer (NSCLC) that has epidermal growth factor receptor (EGFR) mutations...
FLAURA was an important third trial that moved osimertinib to the first line of treatment by showing delayed resistance and improved clinical outcomes; progression-free survival was 18.9 months, and overall survival was 38.6 monthsin the non-paywalled context part of the abstract; the Planchard+2024 research paper itself concludes that
First-line treatment with osimertinib–chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR-mutated advanced NSCLCand followup NEJM correspondence
doubt[s] that up-front combination therapy is better than sequential treatment. I would suggest starting with properly worded and sourced edits on osimertinib and non-small-cell lung cancer. Boud (talk) 11:22, 8 October 2024 (UTC)
So Wikipedia has numerous articles already converting to a semi-protective format and this one, containing sensitive topics, should be no exception. 172.74.203.83 (talk) 13:40, 5 July 2023 (UTC)
Ajpolino can you check these citations? I thought it odd that the page ranges on the two are identical, and wonder if that's a typo?
SandyGeorgia (Talk) 01:03, 7 July 2023 (UTC)